Maintenance Dosing
TREMFYA® Pen (200 mg)‡
or Prefilled Syringe (200 mg)§
200 mg administered by SC injection at Week 12, and every 4 weeks thereafter
For US Healthcare Professionals
I am a
Ulcerative Colitis Specialist
The only IL-23i for UC that offers one single 200-mg subcutaneous (SC) pen injection for each maintenance dose1-3*
Compared to Skyrizi® (risankizumab-rzaa) and Omvoh™ (mirikizumab-mrkz) maintenance dosing. Skyrizi is not available as an SC pen in UC. Omvoh maintenance dose requires 2 SC injections with a 100-mg pen.
*"Only" based on approved selective IL-23 inhibitors for moderately to severely active UC as of September 2024.1-3
DOSING OPTIONS
TREMFYA® dosing for UC
Induction Dosing1
3 IV Infusions (200 mg)†200-mg IV infusion administered over a period of at least 1 hour
†200 mg/20 mL (10 mg/mL) solution in a single-dose vial.1
OR
One-Press patient-controlled injector (100 mg)¶ or Prefilled Syringe (100 mg)§
100 mg administered by SC injection at Week 16, and every 8 weeks thereafter
Use the lowest effective recommended dosage to maintain therapeutic response.
‡200 mg/2 mL in a single-dose prefilled pen.1
§200 mg/2 mL or 100 mg/mL in a single-dose prefilled syringe.
¶100 mg/mL in a single-dose One-Press patient-controlled injector.
‡200 mg/2 mL in a single-dose prefilled pen.1
§200 mg/2 mL or 100 mg/mL in a single-dose prefilled syringe.
¶100 mg/mL in a single-dose One-Press patient-controlled injector.
Pretreatment Evaluations: Prior to initiating treatment with TREMFYA®, evaluate patients for tuberculosis infection and complete all age-appropriate vaccinations according to current immunization guidelines.
TREMFYA® is intended for use under the guidance and supervision of a physician. TREMFYA® may be administered by a healthcare professional, or a patient may self-inject after proper training in subcutaneous injection technique.1
IL-23i=interleukin-23 inhibitor; IV=intravenous; SC=subcutaneous.
DEVICES
For your patients’ maintenance doses, TREMFYA® is available as 3 different devices1
200 mg/2 mL q4w
TREMFYA® Pen
Not actual size.
TREMFYA® comes in a single-dose prefilled pen containing one 200-mg dose. Each TREMFYA® Pen can be only used one time.
Prefilled syringe
Not actual size.
TREMFYA® comes as a single-dose prefilled syringe containing one 200-mg dose. Each TREMFYA® prefilled syringe can be only used one time.
Also in
100 mg/mL q8w1
One-Press
Not actual size.
TREMFYA® comes in a single-dose One-Press patient-controlled injection containing one 100-mg dose. Each One-Press injector can be only used one time.
Prefilled syringe
Not actual size.
TREMFYA® comes as a single-dose prefilled syringe containing one 100-mg dose. Each TREMFYA® prefilled syringe can be only used one time.
At induction, there is a 200-mg IV infusion administered over at least 1 hour at Week 0, Week 4, and Week 8.1
In maintenance, once you have determined the appropriate dose for your patient, you and your patient can choose which device may be best suited for them.
Use the lowest effective recommended dosage to maintain therapeutic response.
Please see the full Instructions for Use for TREMFYA® Pen, One-Press patient-controlled injector, and prefilled syringe.
PRESCRIBING TREMFYA®
Write 2 prescriptions for TREMFYA®1
Write 1 prescription for induction dosing and 1 prescription for maintenance dosing
Write one Rx for TREMFYA® UC IV Induction (200 mg IV q4w).*
The recommended induction dosage of TREMFYA® is 200 mg administered by intravenous infusion over a period of at least 1 hour at Week 0, Week 4, and Week 8.
Write one Rx for TREMFYA® UC SC Maintenance (200 mg SC q4w or 100 mg SC q8w).
The recommended maintenance dosage of TREMFYA® is:
• 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter†‡
OR
• 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter‡§
Use the lowest effective recommended dosage to maintain therapeutic response.
Please refer to the full Prescribing Information for the complete dosing information.
Pretreatment Evaluations: Prior to initiating treatment with TREMFYA®, evaluate patients for tuberculosis infection and complete all age-appropriate vaccinations according to current immunization guidelines.
TREMFYA® is intended for use under the guidance and supervision of a physician. TREMFYA® may be administered by a healthcare professional, or a patient may self-inject after proper training in subcutaneous injection technique.1
* 200 mg/20 mL (10 mg/mL) solution in a single-dose vial.
† 200 mg/2 mL in a single-dose prefilled pen.
‡ 200 mg/2 mL or 100 mg/mL in a single-dose prefilled syringe.
§ 100 mg/mL in a single-dose One-Press patient-controlled injector.
IV=intravenous; q4w=every 4 weeks; q8w=every 8 weeks; SC=subcutaneous; SUBQ=subcutaneous.
*200 mg/20 mL (10 mg/mL) solution in a single-dose vial.
†200 mg/2 mL in a single-dose prefilled pen.
‡200 mg/2 mL or 100 mg/mL in a single-dose prefilled syringe.
§100 mg/mL in a single-dose One-Press patient-controlled injector.
IV=intravenous; q4w=every 4 weeks; q8w=every 8 weeks; SC=subcutaneous; SUBQ=subcutaneous.
These videos are not meant to replace the Instructions for Use (IFU) that are supplied with TREMFYA®. Instruct patients to read the IFU before using their TREMFYA® Pen, TREMFYA® prefilled syringe, or One-Press patient-controlled injector and each time they get a refill. Please see the full IFU for TREMFYA®.
TREMFYA® Pen Demonstration
TREMFYA® Syringe Demonstration
TREMFYA® One-Press Demonstration
TREMFYA® is intended for use under the guidance and supervision of a physician. TREMFYA® may be administered by a healthcare professional, or a patient may self-inject after proper training in subcutaneous injection technique.
References: 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie Inc. 3. Omvoh™ [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.